Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | FYN | P06241 | 2/20 | 0.49 |
| ▸ | LYN | P07948 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | STK3 | Q13188 | 2/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.49 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.49 |
| ▸ | STK16 | O75716 | 1/20 | 0.49 |
| ▸ | STK10 | O94804 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647084 | 0.87 | CHEK1 (0.54) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL647845 | 0.85 | PLK4 (0.51) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL647153 | 0.85 | AURKA (0.51) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL28779314 | 0.84 | PLK4 (0.53) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL645029 | 0.83 | CDK9 (0.54) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL645313 | 0.82 | CDK9 (0.51) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL645077 | 0.82 | CHEK1 (0.54) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL644220 | 0.81 | PLK4 (0.55) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL13515049 | 0.81 | CHEK1 (0.53) | AURKAABL1EGFRFYNLYN | |
| SCHEMBL645095 | 0.81 | MAP3K11 (0.58) | AURKAABL1EGFRFYNLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | claimed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | claimed |
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20120095233-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8119655-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-21 | — | — | US | disclosed |
| EP-2133349-B1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100331357-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2252291-A1 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| EP-2223925-A1 | Kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20090312288-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2133349-A1 | Kinase inhibitors | Takeda San Diego, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009107877-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-03 | — | — | WO | disclosed |
| EP-2081930-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331357-A1 | PHARMACEUTICAL COMPOSITION | ABCG2, GYS2, CEL | AURKA 2328/4885ABL1 3499/4885EGFR 3762/4885 |
| US-20120095233-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | AURKA 220/4885ABL1 27/4885EGFR 378/4885 |
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | AURKA 174/4885ABL1 27/4885EGFR 349/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | AURKA 220/4885ABL1 27/4885EGFR 378/4885 |
| US-20090312288-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | AURKA 220/4885ABL1 27/4885EGFR 378/4885 |
| US-20100190816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | AURKA 174/4885ABL1 27/4885EGFR 349/4885 |
| US-20120252761-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | AURKA 220/4885ABL1 27/4885EGFR 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.